Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy

BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled corticosteroid (ICS)/long-acting beta(2) agonist (LABA) treatment approved in the United States, Canada and Europe for the long-term maintenance therapy of COPD. We report data from mixed treatment comparisons (M...

詳細記述

保存先:
書誌詳細
出版年:Respir Res
主要な著者: Stynes, Gillian, Svedsater, Henrik, Wex, Jaro, Lettis, Sally, Leather, David, Castelnuovo, Emanuela, Detry, Michelle, Berry, Scott
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2015
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4339422/
https://ncbi.nlm.nih.gov/pubmed/25849223
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-015-0184-8
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料